Expert Ratings For Corteva
Portfolio Pulse from Benzinga Insights
Corteva (NYSE:CTVA) has been evaluated by 9 analysts over the last three months, showing a diverse range of opinions. The average 12-month price target for Corteva has been raised to $60.78, up 5.01% from the previous target of $57.88. Analysts from firms including Loop Capital, Oppenheimer, and RBC Capital have raised their price targets, indicating a positive outlook on the company. Despite this, Corteva faces financial challenges with a -3.08% decline in revenue growth and below-average profitability metrics. The company, a leader in seed and crop chemical products, was spun off from DowDuPont in 2019.
March 01, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Corteva's average 12-month price target has been raised to $60.78, indicating a positive outlook from analysts despite recent financial challenges.
The increase in the average price target to $60.78, up 5.01% from the previous target, suggests analysts are optimistic about Corteva's future performance. This optimism is supported by several analysts raising their price targets. However, the company's financial challenges, such as a -3.08% decline in revenue growth and below-average profitability metrics, present risks that investors should consider. The positive adjustments in price targets by analysts from reputable firms indicate a belief in the company's potential to overcome these challenges.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100